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Hepatitis C is the disease of liver caused by hepatitis C
virus (HCV). Due to its widespread impact on human
population, there is continued surge for new therapeutic
agents to treat and reduce HCV. Hence, nowadays HCV
is considered as global burden throughout the world.
Advancements in therapeutic invention and clinical out-
comes are dependent on HCV genome and diversity in
nature, pathogenesis, dietary factors, social, economic
and environmental factors. In this review we have
focused mainly on HCV genome, its history and clinical
outcomes from its discovery to present day research.
In this article the authors have reviewed the published
data from year 1997 to 2014. The topics of main concerns
were hepatitis C with diverse nature and recent advances
in the treatment of chronic hepatitis C. The authors used
MeSH terms “Hepatitis C Virus (HCV)”, recent advances
in the treatment of “HCV”, “HCV and Immunity”,
“vaccination”, or “Interferon therapy” to search the
PubMed database.
All relevant studies identified were included and are
described according to the subheadings. Recent
advancement in molecular biology and experimental
techniques has opened new insights into the pathophysi-
ology of HCV which is helping in combating this life
threatening disease.
Although the response to current treatment regimen for
HCV is improved however complete recovery from the
disease is still a challenge which requires more extensivehis is an open access article under the CC BY-NC-ND license
16/j.jtumed.2014.08.004
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Hepatitis C is a complex disease of liver. Due its wide-
spread nature and global burden, this disease has always
attracted attention for insight into its causative agent, hep-
atitis C virus (HCV), and for the development of new ther-
apeutic approaches. Even after twenty four years of its
discovery, HCV continues to be a major cause of concern
and a huge burden on public health systems worldwide.
WHO estimates that minimum of 3% of the world’s popu-
lation is chronically infected with HCV.1,2 As cited in various
research articles that HCV has caused massive impact on
public health, and around 170 million people in the world
are infected with HCV, with an estimated 3 to 4 million
new infections global per year.3 It causes infection in two
phases, first involve acute attack that last for few weeks
and if untreated then it may persist for long time that is
termed as chronic hepatitis C. This chronic infection may
often lead to chronic liver disease (CLD) that may
ultimately lead to even hepatic failure.4
This review covers the basic structure of HCV and new
insights in development of novel treatment method and stra-
tegies to counteract this aggressive disease. Persistent virus
infectionwithHCVoften leads to cirrhosis andhepatocellular
carcinoma (HCC). As cited in literature that it is difficult to
combat the infection due to diverse nature of this virus. The
recent research is directed at genome level and has discovered
many antiviral therapies providing evidences about the new
antiviral drugs against HCV. Presently in market, available
treatment option is a long-acting pegylated-interferon-alpha,
given in combination with nucleoside analog ribavirin, which
is quite effective but due to adverse reaction, relapses, and
poor health condition many of the patients resort to discon-
tinue the therapy.5 Also various traditional herbal medicines
are available in the market practiced by Unani or Ayurvedic
or traditional Chinese medicine (TCM) practitioner in
Pakistan, India, and China. These medicines are alternative
treatment option for this chronic disease, but due to lack of
advance research on scientific basis, these medicines are not
widely utilized as compared to allopathic medicine. It is
strongly suggested that these traditional medicines should
be justified on scientific grounds and comparative clinical
trials on large scale are direly needed, which might be
fruitful in identifying curative medicinal herbs. This may
create alternate options for researches to reduce the global
burden of diseases by sorting natural source of treatment.
Molecular studies of HCV had started with the successful
cloning of its genome in 1989. A major milestone was
achieved with the recent development of a robust cellculture system for HCV propagation. HCV proteins
assemble and form replication complexes on modified host
membranes, called as membranous webs. Even though
HCV is detected and targeted by host immune mechanisms,
it establishes and maintains a life-long persistent infection.
It evolved different strategies for its survival in hostile cellular
environments. The HCV population is well known to rapidly
change during the course of natural infection, thereby,
escaping the immune surveillance. For survival it may select
variants that are resistant to antiviral drugs. The extremely
complex nature of this virus lifecycle had left complication for
discovery of new therapies. A complete understanding of the
functional roles played by the HCV proteins during its life-
cycle is vital for developing a successful cure.History of hepatitis C
The HCV belongs to the most successful of all persistent
human viruses. With a compact RNA genome thought to
encode only 11 proteins, HCV persists in up to 70% of those
infected by successfully undermining virus-specific immunity
while leaving host defenses to other infectious agents intact.
An estimated 170 million individuals are infected worldwide,
and approximately 38,000 new infections occur annually in
the United States alone.6 Twenty percent of persistently
infected individuals will develop liver cirrhosis, and
approximately 2.5% progress into hepatocellular carcinoma
(HCC). Furthermore, current anti-viral therapy is effective
in only 50e60% of all the patients treated but is much
expensive, and at same time it exerts side effects.7 The precise
understanding of adaptive immunity response against the
virus is crucial for the design of effective strategies in order
to control HCV both in the infected and healthy individuals
as well for prevention from this infection. The outcome of
HCV infection is determined within six months of exposure
to the virus. Acute infection is often unrecognized because
symptoms are usually mild or absent. After first attack that
is called acute, it may turn into chronic infection which if
not treated at earlier stage, may initiate innate immunity
against this virus.8 It is reported that there is strong relation
between adaptive immunity and HCV. Ge et al. described
that there is involvement of humoral immunity in natural
clearance of this virus and treatment response of interferon
as well.9 It has been described that there is involvement of
antiviral CD4þ helper cells and the CD8þ cytotoxic T cells
in acute phase. As a corollary to this response, memory
cells are produced in the body that helps to reduce the risk
of re-exposure of this infection. It is reported that there is
significant relation of polymorphism of 3 kb upstream of
IL28Bwith pegylated interferon and ribavirin for treating the
chronic hepatitis C due to genotype 1. This shows that gene
product associated with natural clearance of this infection is
involved in innate immune response against HCV. It was
experimentally proved in vitro and in vivo that interferon
therapy shows strong antiviral activity against genotype
1.10,11 The IFN-l proteins, encoded by the IL28A/B and IL29
genes, were identified in 2003.12,13 The specific target of IFN
to study underlying gene response (i.e. IL28B) and cell
signaling are potential target for development of new
antiviral drugs.9 For novel antiviral therapies it is necessary
to target structural proteins variants that are vital for viral
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RNA-dependent RNA polymerase.14,15 It is imperative to
explore the relationship between functional and structural
equivalence of this virus and to determine the specific
location and strain of genome that may help in vaccine
development against HCV.16
Virology
Hepatitis C is a single stranded RNA virus that belongs to
a family flaviviridae. In 1989 HCV was identified as major
causative agent of hepatitis C.17 HCV is a small (w55e
65 nm), spherical in shape, enveloped, hepatotropic RNA
virus that causes acute and chronic hepatitis in human.18 It
encodes a protein chain of 3010 amino acids and contains
structural and non-structural proteins.19,20 HCV consist of
a 9.6-kb single-stranded positive sense RNA genome with a
50 untranslated region (UTR) that functions as an internal
ribosome entry site, a single long open reading frame
encoding a polyprotein of approximately 3000 amino acids
(aa) and a 30 UTR. This polypeptide is post-translationally
cleaved by host cell peptidases (proteases) to yield three
structural proteins named E1, E2, core, p7 and by viral
proteases, which generate the six non-structural proteins
named as NS2, NS3, NS4a, NS4b, N4a and NS5B.21e25 By
analogy to related positive-strand RNA viruses, replication
occurs by means of a negative-strand RNA intermediate and
is catalyzed by the NS proteins, which form a cytoplasmic
membrane-associated replicase complex.26Figure 1: Stages of liver damage. This figure shows how normal he
hepatocellular carcinoma or liver failure.Its various genotypes (GT) identified are 1 2, 3, 4, 5, 6, and
7 that shows the distribution of this virus worldwide.27,28
Most common genotypes are GT 1e4.The seven confirmed
genotypes comprise 67 subtypes, 20 provisionally assigned
subtypes, and 21 unassigned subtypes. The natural course
of infection seems to vary with the genotype; some are
associated with a higher chance of acute infection being
cleared i.e. GT3 is more likely to clear compared with
GT1).29,30 In fact, HCV circulated in infected individuals
as a population of diverse but closely related variants
termed as “quasispecies”. The incubation period of HCV is
6e8 weeks. It is referred as silent disease or silent killer”
because it remains asymptomatic and undetected at early
stage rendering the early treatment of HCV infection
difficult. HCV does not resolve in majority of cases and
later on leads to greater complication that would damage
liver at large. During natural course of infection,
neutralizing antibodies (that mask the antigenicity) are
produced that is why it escape surveillance.31 This disease
has no constant outcomes; it can vary from mild to severe
and may cause fibrosis. The flow chart that is given below
in Figure 1 describes the stages of liver damage from acute
manifestation of HCV till HCC. This acute type may
resolve in about 20% of cases while remaining 80% of
cases are converted into chronic clinical presentation. In
the chronic condition it presents with three different stages
i.e. mild, moderate and severe. If it is not treated at early
stage then the outcome of all these is liver cirrhosis that
may lead to either HCC. The process of disease in whichalthy liver develop into hepatitis C, fibrosis, cirrhosis and even
A. Nawaz et al. 135liver is affected and being diseased from healthy liver to reach
cirrhosis or HCC is given in Figure 2.
Mode of transmission
Parenteral route is primarily source of spread of hepatitis
C. Those who are at higher risk for getting hepatitis C are
intravenous drug users (90%), and blood transfusion, blood
products such as hemophiliacs and during surgical pro-
cedures whereas 0.4e3% transmission occur by sexual or
intimate contact much less than hepatitis B (HBV).32
Approximately 3e5% transmission occurs through mothers
infected with HCV to newborn infants. This transmission of
infection from mother to infant is mainly due to vertical
transmission and there are no or very rare chances from
breastfeeding because this virus become inactivated in the
digestive tract of infant.33e35 Through needle stick injury
there is 5% chances of transmission of HCV.36 In saliva
and breast milk, HCV has been found but not documented
to spread through breast milk.37 Needle stick open wounds
at work may be affected with HCV or transmission of HCV
occurs through some other potential source which may
include the sharing or contact sports and other activities i.e.
slam dancing which may relate to blood exposure.27,38,39
Through improper sterilization techniques, the HCV can
spread from one person to another by tattooing dyes,
stylets, inkpots, and piercing etc. Toothbrushes, razors,
cuticle scissors or excessive visits to barbers can be the
source of transmission or spread of HCV to healthy person
by sharing these with infected individuals.40Figure 2: History of HCV infection from acute phase to HCC;
Exposure of HCV may lead to acute infection and if not treated
then it may lead to chronic infection in 85% of cases. From
chronic hepatitis to cirrhosis it may take approximately 20 years to
cause cirrhosis or end stage liver disease.
(Reference: Di Bisceglie A, et al. Hepatology. 2000; 31:1014e
1018).Natural course of pathogenesis
After the infection with HCV, the virus can be detected
within 1e4 weeks prior to the increase in liver enzymes.41 The
pathogenicity of liver is so complex that it cannot be
explained clearly even after 24 years of research from its
discovery. In 25% of cases, the jaundice may appear in
HCV positive patients but mostly remains symptomless
that are why it is not identified at very early stage.42
Chronic infection will develop in more than 85% of HCV
positive patients as shown in Figure 2. In most of the
cases, this infection is cleared automatically by powerful
immune system i.e. natural or cell mediated immunity. In
some cases with weak immune system, antibodies are not
produced against HCV and ultimately are not detected by
either polymerase chain reaction (PCR) for HCV RNA or
anti-HCV antibodies test.43
Inbuilt immunity: The invasion of HCV occur mostly
when the natural immunity of human being become weak
and concentration of invading agent become excessive or
more copies are formed. When the natural immunity be-
comes weak or decreased due to any impeding factors, there
are increased chances of invasion of HCV causing severe
disturbance in structure and function of liver. There is also
association of autoimmunity and cryoglobulinemia with
hepatitis C.44,45 Some of the evidence proved that cell
mediated immunity (CD8þ) have a main role in HCV
pathogenesis and killing of HCV infected hepatocytes.41
Humoral immunity: Hepatitis C infection is not cleared
spontaneously in 85% of infected individuals. When anti-
HCV antibodies are positive in HCV persistent infection, it
means these antibodies are not enough to clear the infection
in chronic infected patients. To fight against HCV, the hu-
moral immunity plays an important role to assist in direct
neutralization of cell free virions. The humoral immunity has
very limited role in the cell to clear off the HCV completely.46
Cell mediated immunity: The host shows response against
HCV infection by helper T-cells and T-cytotoxic cells. In
resolution of HCV infection, T-helper and T-cytotoxic cells
plays a major role in providing immunity at cellular level and
offer a very powerful defense mechanism. The activated T-
cells can kill HCV hidden in cells of liver and can make he-
patocytes and kupffer cells so strong that they cannot exhibit
any injurious or harmful event in liver.47Clinical presentation of hepatitis C without cirrhosis
Although HCV affects liver but it exert effects on almost
every organ as well as whole body. In 14% of infected pa-
tients with HCV, signs and symptoms of hepatitis C are
positive while 86% of the infected patients remains asymp-
tomatic.48 HCV has deteriorating effect on whole body
systems which produce exacerbating symptoms mostly
include fatigue, fever, epigastric pain, burning micturation,
heart burn, burning palm and sole, chills, fluid retention
and muscle pain.49 These may also include weakness and
generalized itching. There is also involvement of systemic
(gastrointestinal), cognitive, mood and nervous systems in
this disease to display the relative intensity of symptoms. It
may also include hypoglycemia, hyperglycemia, chest pain,
menstrual changes, palpitations and also sexual anomalies.49
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Gold standard to investigate hepatitis C starts with sero-
logical blood test that is specifically designed for the detec-
tion of HCV. These anti-HCV antibodies may be diagnosed
in nearly 80% of cases within 15 weeks of exposure. In gen-
eral, anti-HCV antibodies have a very strong positive pre-
diction value after exposure. However, in some of the cases
these are not detected and missed in patients who have not
developed these antibodies or the level of antibodies is
insufficient to be diagnosed. Those patients who are immu-
nocompromised can never develop antibodies to HCV and
anti-HCV test could not be ascertained as positive. For this
possibility of molecular RNA testing should be done even
when anti-HCV test is negative and the serum alanine ami-
notransferases and alkaline phosphatase are found raised.50
Management
The management of hepatitis C includes different ways to
control and combat this disease. The major line of treatment
may include; to treat actual cause with immunostimulants,
antioxidants, blood purifiers, diuretics, hepatoprotectives
and to change the internal environment in which HCV
cannot survive.
New insights and prospective
The effectiveness of interferon alpha 2b and ribavirin
combination therapy in the treatment of naı¨ve chronic hep-
atitis C patients have been cited in the literature.51 Gary et al.
described that combination of seven botanical drugs Sho-Sai-
Ko or xiao-chai-hu-lang in China utilizes for the treatment of
hepatitis C have improved the liver pathogenicity in selected
hepatitis C patients.52 We also conducted similar study on
Hepcinal, a coded herbal formulation, comprised of five
botanical drug components (namely: Silybum marianum,
Picrorrhiza kurroa, Glycyrrhizaglabra, Tamarix gallica,
Rosa damascena) have shown marked clinical improvements
in the signs and symptoms of this disease (Unpublished
data). It is recently reported that antibodies produced from
different genotypes of HCV may neutralize the
pseudoparticles to control the infection naturally.
Pseudoparticles are genetically tagged HCV particles
harboring unmodified E1 and E2 glycoproteins. High
infectivity of these particles allowed the precise
investigation of HCV E1 and E2 glycoproteins and their
potential receptors in cell entry, HCV host-range, and
neutralization by antibodies fromHCV patient sera.53,54 This
suggests that a broad cross-neutralizing antibody to HCV
may exist and could be exploited in vaccine strategies. This
concept of neutralizing the antibodies in pseudoparticles
infectivity may explore that acute infection in some cases may
recover automatically during this neutralizing process of
inbuilt immune activity.55 The relative roles of humoral and
cellular immunity in recovery remain unclear. Continuous
effort from several years helped to explain the sophisticated
battle that is initiated in the infected host. The RNA virus
cannot integrate into the host genome and it may develop
the mechanisms to persist and to evade the host’s innate
and the adaptive immune mechanisms. The virus has theability to inhibit the induction of the type-1 interferon, may
inhibit the NK cells and readily produces escape mutants to
cytotoxic T lymphocyte and neutralizing antibodies directed
to the amino-terminal region of gpE2.56e65 It may also inhibit
the binding of the virion-neutralizing antibodies by masking
with the lipoproteins.66 Bowen and Walker found that cell
mediated immunity play critical role for preventing the
HCV persistence.8 They concluded by their observation that
immunity has major role in the prevention from different
genotypes and open new hopes for development of safe and
effective vaccine. They also found close relation between
CD4þ TH cells and HCV infection. These cells may be the
best candidate in future study to cure and prevents the
progression of this disease.8 The next generation of direct
acting antivirals and the first interferon-free regimen for the
treatment ofHCVhave recently been approved.Over the next
one or two years, several new agents (protease inhibitors and
NS5B inhibitors) and classes (NS5A inhibitors) of direct
acting antivirals are likely to be licensed. Newer protease in-
hibitors will broaden the range of peginterferoneribavirin
containing regimens available, but most importantly the op-
tions available for interferon-free regimens will grow. The
combinations of sofosbuvireledipasvir, sofosbuvireGS-
9669, and the regimens of ABT-450eritonavireombitasvire
dasabuvir, and daclatasvireasunaprevireBMS-791325 are
expected to be approved in the near future. These interferon-
free regimens could enable many patients with HCV (even
those with cirrhosis and those who have not responded to
previous protease inhibitor based treatment) to be cured with
an oral course of antivirals without the use of interferon and
its associated side effects. Despite this optimism, challenges
remain, particularly in the treatment of patients with HCV
GT3, cirrhosis, hepatic decompensation, and liver
transplantation.29,67
Ralston et al. reported on vaccine development and found
promising findings using recombinant technology.68 For
vaccine development they involved HCV recombinant
glycoproteins i.e. gpE1 and gpE2 derived from mammalian
cells, that can form a non-disulphide link to resemble the
pre-virion envelope structure. They found that vaccinated
experimental animals (anti-gpE1/gpE2 antibody titres) were
protected from the infection when vaccinated.69 They had
used the sensitive RTePCR assays to analyze viraemia
from blood or liver samples and found no viraemia in these
experimental animals. They suggested that this response
may be due to the sterilizing immunity correlated directly
with anti-gpE2 antibody titers that may prevent the bind-
ing of gpE2/virus itself to the CD81 cells and it is important
receptor for HCV and for the cell entry of the lentiviral/HCV
pseudoparticles.52,70e72 Therefore, they also found that
lower-responding animals were infected again and mainly
they bypass the acute infection which in the humans, can be
associated with the chronic liver disease.67,73e76 They
concluded that there is low rate of carriers in vaccinated as
compared with the control group that was not
immunized.67,73 It was inferred in many research studies
that recovery from the acute HCV infection correlate with
the cellular immunity against this virus, and for the
development of vaccine it may involve both humoral and
cell mediated immunity against the HCV.77 Arora et al.
demonstrated high rates of cure for the HCV treatment
delivered through different model in community-based
A. Nawaz et al. 137study.78 They found comparable sustained virologic
response (SVR) rates in overall response and also in
genotype 1.79e81Outlook and future directions
It is clearly an exciting time in HCV research, and rapid
progress should be made now due to availability of complete
cell culture systems. It is expected that in vivo and in vitro
study should be conducted by using human HCV and
thereafter monitor its replication and then treat by using
targeted medicine with and without diet restriction. Massive
and descriptive studies should be conducted from baseline to
investigate exact nature and replication processes of virus
and correlation of immunity or nerve impulses should also be
analyzed. Early enhancement in development strategies
against this virus is necessary to overcome its circumstances
to remain in control, reduce danger and threat to lead
healthy life. Many promising agents are in the pipeline to
bring about evidence based therapies.
The improved response rates and treatment duration of
hepatitis C with both allopathic and traditional medicine are
delineated in literature; however, limitation still exists for its
total curative function. Research in hepatitis C field should
move from small, single center and go beyond large multi-
center strategies as more and more information is available
from genetics to immunology perspective. However, more
stress is needed to execute surveillance for cirrhosis and
hepatitis C for standard care.Author contribution
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